.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD04_TrastuzumabDeruxtecan.TrastuzumabDeruxtecan .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FD04_TrastuzumabDeruxtecan.TrastuzumabDeruxtecan| name: | TrastuzumabDeruxtecan | |
| ATC code: | L01FD04 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 5.4 | mg |
| volume of distribution: | 2.77 | L |
| clearance: | 0.42 | L/day |
| other parameters in model implementation | ||
Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) composed of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor. It is indicated for the treatment of HER2-positive breast cancer and other HER2-expressing cancers. The drug is approved for clinical use in multiple countries and is typically used in patients who have received prior anti-HER2 therapies.
Pharmacokinetics in adult patients with HER2-positive breast cancer receiving 5.4 mg/kg intravenously every three weeks.
Doi, T, et al., & Tamura, K (2017). Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet. Oncology 18(11) 1512–1522. DOI:10.1016/S1470-2045(17)30604-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29037983